MarketCapExport financials
Alphatec Holdings (ATEC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Alphatec Holdings Financial Ratios 2025-2008 | ATEC
Brief overview of Alphatec Holdings's valuation and returns
The comparison uses the five latest available annual observations between 2021 and 2025.
The current valuation set is P/S 2.7x (median 3.87x), P/B 2.61x (median 2.32x). The multiple basket looks neutral against its history, differing from median levels by roughly -8.6%.
Capital efficiency is characterized by ROE -11.5%, ROA -18.1%, ROCE -6.6%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Current PEG is 0.65x; the market pays comparatively little per unit of expected growth.
The time from paying for inputs to receiving cash fell from 250.6 days to 240.1 days. Cash turnover improved.
Conclusion
Alphatec Holdings's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Alphatec Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.4 | -9.6 | -10.0 | -10.1 | -7.4 | -13.6 | -6.4 | -1.9 | -18.4 | -0.8 | -0.2 | -9.7 | -2.6 | -9.9 | -7.2 | -337.7 | - | - | |
P/S |
2.7 | 2.5 | 3.9 | 4.3 | 4.4 | 7.4 | 3.2 | 0.6 | 0.4 | 0.2 | 0.2 | 0.6 | 1.0 | 0.8 | 0.8 | 28.2 | - | - |
EPS |
-1.0 | -1.1 | -1.5 | -1.5 | -1.5 | -1.2 | -1.1 | -1.2 | -0.2 | -3.5 | -1.8 | -0.1 | -0.8 | -0.2 | -0.2 | -0.2 | -0.3 | - |
EV (Enterprise Value) |
1.91 B | 1.41 B | 1.64 B | 1.44 B | 873 M | 968 M | 443 M | 137 M | 131 M | 141 M | 214 M | 301 M | 387 M | 267 M | 261 M | 4.82 B | -10.1 M | -18.3 M |
EBITDA per Share |
-0.03 | -0.4 | -0.97 | -1.02 | -1.05 | -0.71 | -0.727 | -0.545 | -0.545 | -1.23 | -0.268 | 0.895 | -1.63 | -0.642 | -1.56 | 0.07 | - | - |
EV/EBITDA |
-411.0 | -24.5 | -14.0 | -13.6 | -8.6 | -19.8 | -9.8 | -3.7 | -8.7 | -5.0 | -49.9 | 25.8 | -19.0 | -35.8 | -14.6 | 884.1 | -5.7 | - |
PEG |
0.65 | 2.29 | -0.7 | -0.66 | -1.58 | -0.2 | -0.7 | 0.0 | -0.19 | -0.01 | 0.0 | -0.11 | 0.01 | -0.31 | 0.19 | - | - | - |
P/B |
2.6 | 2.0 | 2.3 | 2.9 | 1.9 | 4.1 | 8.3 | 3.1 | -1.6 | -0.6 | -1.1 | 0.8 | 1.3 | 0.6 | 0.7 | 12.9 | - | - |
P/CF |
45.7 | -34.8 | -23.8 | -20.3 | -14.5 | -23.2 | -7.9 | -1.7 | -2.6 | -1.3 | -19.7 | -3.9 | -29.4 | -26.4 | 35.6 | -326.8 | - | - |
ROE % |
-1153.69 | 1144.21 | -238.92 | 436.42 | -177.30 | -60.82 | -130.65 | -164.87 | 8.61 | 72.10 | 488.51 | -8.65 | -47.90 | -6.29 | -9.04 | -5.39 | -17.76 | - |
ROA % |
-18.12 | -20.90 | -23.18 | -29.04 | -25.00 | -30.24 | -33.54 | -22.38 | -2.71 | -31.77 | -121.79 | -3.73 | -22.49 | -4.05 | -6.05 | -3.81 | - | - |
ROCE % |
-660.94 | 961.03 | -221.97 | 423.96 | -158.73 | -45.32 | -28.95 | -20.22 | -13.94 | -21.00 | -28.54 | 0.91 | -6.22 | -2.69 | -4.41 | -4.42 | -13.61 | - |
Current Ratio |
- | - | - | - | - | - | 3.0 | 2.5 | 2.2 | 1.8 | 0.8 | 1.8 | 1.4 | 2.1 | 2.0 | - | - | - |
DSO |
43.1 | 46.4 | 50.2 | 53.0 | 49.1 | 50.0 | 52.0 | 61.5 | 53.2 | 56.2 | 75.5 | 71.3 | 73.8 | 76.3 | 77.0 | 42.3 | - | - |
DIO |
270.8 | 304.1 | 252.8 | 299.3 | 294.1 | 348.3 | 355.0 | 369.0 | 252.8 | 249.0 | 257.2 | 246.4 | 194.6 | 257.2 | 207.5 | 163.4 | - | - |
DPO |
73.8 | 99.4 | 88.8 | 93.7 | 92.6 | 109.3 | 79.2 | 56.4 | 35.9 | 72.0 | 81.1 | 59.8 | 50.1 | 98.9 | 78.6 | 50.5 | - | - |
Operating Cycle |
313.9 | 350.5 | 303.0 | 352.4 | 343.2 | 398.3 | 407.0 | 430.4 | 306.0 | 305.2 | 332.6 | 317.7 | 268.4 | 333.4 | 284.5 | 205.7 | - | - |
Cash Conversion Cycle |
240.1 | 251.2 | 214.2 | 258.7 | 250.6 | 289.0 | 327.8 | 374.0 | 270.0 | 233.2 | 251.5 | 257.9 | 218.3 | 234.5 | 205.9 | 155.2 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Alphatec Holdings
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.03 | -0.16 | -0.22 | - | -0.19 | -0.27 | -0.35 | - | -0.28 | -0.29 | -0.34 | - | -0.35 | -0.43 | -0.4 | - | -0.35 | -0.36 | -0.43 | - | -0.43 | -0.39 | -0.26 | - | -0.24 | -0.25 | -0.33 | - | -0.26 | -0.27 | -0.29 | - | -0.22 | -0.21 | -0.09 | - | -0.23 | -0.24 | -0.61 | -0.49 | -1.6 | -0.05 | -0.07 | -1.18 | -1.61 | -0.04 | -0.05 | - | -0.03 | -0.03 | -0.07 | -0.62 | -0.15 | -0.05 | -0.03 | -0.06 | -0.03 | -0.07 | -0.01 | -0.18 | -0.01 | -0.03 | -0.02 |
EBITDA per Share |
0.05 | 0.24 | -0.02 | - | 0.28 | 0.01 | -0.17 | - | -0.12 | -0.14 | -0.18 | - | -0.23 | -0.34 | -0.26 | - | -0.26 | -0.33 | -0.32 | - | -0.17 | -0.31 | -0.17 | - | -0.08 | -0.1 | -0.25 | - | -0.11 | -0.15 | -0.2 | - | -0.06 | -0.09 | 0.06 | - | 0.31 | 0.27 | -0.17 | - | 0.68 | 0.83 | 0.05 | - | -18.2 | 0.07 | 0.05 | - | 0.16 | 0.12 | - | - | 0.07 | 0.1 | 0.05 | - | 0.17 | 0.09 | 0.06 | - | 0.14 | 0.07 | 0.03 |
ROE % |
837.01 | 426.27 | 273.05 | -361.06 | 2547.60 | 2558.24 | 2602.18 | 2541.78 | 2638.37 | -87.80 | 224.52 | 353.66 | 529.76 | 126.93 | -153.67 | -228.25 | -266.75 | -460.74 | -175.65 | -77.55 | -89.61 | -63.28 | -61.34 | -40.19 | -73.57 | -90.01 | -107.57 | -91.61 | -144.84 | -151.72 | -134.12 | -104.40 | -92.63 | -29.28 | 31.67 | 42.57 | 53.06 | 74.36 | 76.85 | 72.10 | 88.69 | 493.80 | 491.98 | 488.51 | 461.25 | 21.04 | 8.30 | -8.65 | -43.65 | -50.06 | -50.83 | -47.90 | -14.89 | -7.47 | -7.35 | -6.32 | -10.65 | -10.15 | -8.79 | -9.04 | -0.53 | -1.24 | -0.76 |
ROA % |
-11.82 | -16.34 | -19.69 | -15.44 | -20.76 | -22.42 | -23.47 | -16.86 | -23.23 | -26.10 | -28.44 | -22.18 | -29.31 | -30.19 | -29.78 | -22.14 | -29.34 | -30.87 | -29.29 | -21.52 | -27.52 | -26.37 | -25.64 | -19.98 | -28.55 | -29.87 | -31.45 | -23.52 | -30.74 | -27.64 | -21.80 | -14.17 | -17.88 | -13.84 | -14.89 | -13.41 | -18.03 | -28.89 | -31.26 | -31.77 | -33.92 | -128.86 | -126.00 | -122.10 | -115.41 | -6.77 | -4.92 | -3.73 | -20.18 | -23.26 | -23.70 | -22.49 | -7.37 | -4.05 | -4.44 | -4.05 | -7.00 | -6.71 | -5.87 | -6.05 | -0.36 | -0.83 | -0.51 |
ROCE % |
158.68 | 244.60 | 280.33 | -141.98 | 2332.54 | 2264.67 | 2204.30 | 2152.77 | 2239.63 | -57.80 | 217.68 | 333.09 | 500.46 | 118.52 | -153.49 | -222.62 | -254.05 | -438.16 | -160.67 | -65.76 | -75.66 | -52.83 | -49.79 | -32.20 | -58.78 | -72.75 | -88.83 | -75.12 | -117.99 | -128.65 | -108.58 | -83.90 | -79.17 | -33.55 | 16.44 | 20.24 | 31.20 | 27.24 | 32.77 | 20.02 | 470.25 | 467.02 | 463.13 | 454.83 | 456.00 | 7.01 | -3.88 | -0.76 | -8.43 | -11.28 | -13.31 | -10.15 | -10.98 | -4.83 | -3.20 | -2.41 | -3.37 | -3.89 | -3.32 | -3.27 | -0.96 | -1.35 | -0.96 |
DSO |
45.6 | 46.3 | 48.4 | - | 44.8 | 45.6 | 46.5 | - | 49.2 | 54.1 | 53.1 | - | 48.0 | 47.7 | 51.2 | - | 48.1 | 45.7 | 53.0 | - | 48.9 | 43.6 | 51.0 | - | 52.1 | 72.5 | 60.1 | - | 50.5 | 53.9 | 58.1 | - | 59.9 | 62.5 | 64.1 | - | 58.5 | 55.5 | 54.4 | 62.4 | 63.2 | 52.4 | 60.5 | 70.5 | 93.9 | 75.0 | 73.9 | 68.8 | 72.3 | 69.4 | 75.9 | 71.2 | 75.2 | 74.0 | 74.5 | 71.0 | 79.9 | 77.6 | 77.9 | 76.9 | 79.9 | 74.8 | - |
DIO |
291.3 | 292.5 | 291.5 | - | 259.4 | 275.4 | 296.9 | - | 337.9 | 345.3 | 321.5 | - | 299.2 | 198.8 | 247.4 | - | 308.4 | 321.1 | 400.7 | - | 351.5 | 310.3 | 384.6 | - | 352.0 | 477.7 | 406.1 | - | 343.2 | 377.1 | 363.4 | - | 386.2 | 404.6 | 399.5 | - | 290.0 | 288.5 | 233.8 | - | 253.1 | 247.8 | 294.5 | - | 352.8 | 218.6 | 257.8 | - | 266.9 | 229.5 | 247.4 | - | 149.9 | 206.8 | 242.5 | - | 270.1 | 257.5 | 268.7 | - | 246.4 | 203.5 | - |
DPO |
89.7 | 83.0 | 71.3 | - | 64.8 | 69.5 | 78.7 | - | 125.8 | 141.3 | 121.3 | - | 112.0 | 72.1 | 87.0 | - | 100.1 | 106.9 | 125.6 | - | 116.2 | 121.1 | 163.8 | - | 134.7 | 182.8 | 127.4 | - | 76.5 | 84.1 | 69.5 | - | 59.1 | 61.9 | 59.0 | - | 41.2 | 41.0 | 51.2 | - | 73.2 | 71.6 | 104.4 | - | 126.1 | 69.0 | 72.3 | - | 64.8 | 55.7 | 61.9 | - | 38.6 | 53.2 | 68.8 | - | 82.5 | 78.7 | 91.5 | - | 93.3 | 77.1 | - |
Operating Cycle |
336.9 | - | 339.9 | - | - | 320.9 | 343.4 | - | 387.1 | 399.4 | 374.7 | - | 347.2 | 246.5 | 298.6 | - | 179.5 | 366.9 | 453.7 | - | 400.4 | 353.9 | 435.6 | - | 404.1 | 550.2 | 466.2 | - | 393.6 | 431.1 | 421.5 | - | 446.1 | 467.1 | 463.6 | - | 348.6 | 344.0 | 288.1 | 62.4 | 316.4 | 300.2 | 355.0 | 70.5 | 446.6 | 293.6 | 331.7 | 68.8 | 339.3 | 298.9 | 323.3 | 71.2 | 225.1 | 280.9 | 317.1 | 71.0 | 350.0 | 335.1 | 346.6 | 76.9 | 326.4 | 278.4 | - |
Cash Conversion Cycle |
247.2 | - | 268.6 | - | - | 251.4 | 264.8 | - | 261.3 | 258.1 | 253.4 | - | 235.2 | 174.4 | 211.6 | - | 129.2 | 260.0 | 328.1 | - | 284.2 | 232.8 | 271.8 | - | 269.5 | 367.4 | 338.8 | - | 317.1 | 347.0 | 351.9 | - | 387.0 | 405.2 | 404.6 | - | 307.4 | 303.0 | 236.9 | 62.4 | 243.2 | 228.5 | 250.6 | 70.5 | 320.5 | 224.6 | 259.4 | 68.8 | 274.5 | 243.2 | 261.5 | 71.2 | 186.6 | 227.7 | 248.3 | 71.0 | 267.4 | 256.4 | 255.0 | 76.9 | 233.0 | 201.3 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Alphatec Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
LivaNova PLC
LIVN
|
$ 91.2 | -3.17 % | $ 4.97 B |  Britain |
 |
LENSAR
LNSR
|
$ 5.46 | -6.51 % | $ 65.3 M |  USA |
 |
Pulmonx Corporation
LUNG
|
$ 2.57 | -9.36 % | $ 105 M | USA |
 |
Penumbra
PEN
|
$ 320.73 | -0.55 % | $ 12.5 B | USA |
 |
InspireMD
NSPR
|
$ 0.64 | -18.18 % | $ 41.2 M |  Israel |
 |
InMode Ltd.
INMD
|
$ 13.42 | -5.53 % | $ 867 M | Israel |
 |
OrthoPediatrics Corp.
KIDS
|
$ 32.1 | -4.21 % | $ 753 M | USA |
 |
Outset Medical
OM
|
$ 4.06 | -8.56 % | $ 61.8 M | USA |
 |
PAVmed
PAVM
|
$ 1.55 | -6.63 % | $ 1.04 M | USA |
 |
AVITA Medical
RCEL
|
$ 15.71 | -3.74 % | $ 438 M |  Australia |
 |
Tactile Systems Technology
TCMD
|
$ 26.38 | -3.31 % | $ 603 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.3 | 1.66 % | $ 41.9 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.01 | -10.88 % | $ 350 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | USA |
 |
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
- | - | $ 462 M | USA |
 |
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 7.38 | 0.96 % | $ 997 M | USA |
 |
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 66.45 | -0.13 % | $ 1.95 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.73 | 0.07 % | $ 4.4 B | USA |
 |
Avanos Medical
AVNS
|
$ 24.99 | - | $ 1.16 B | USA |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
$ 1.92 | -8.57 % | $ 42.3 M | USA |
 |
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
- | - | $ 140 M | USA |
 |
GBS
GBS
|
- | -0.57 % | $ 7.12 M | USA |
 |
NanoVibronix
NAOV
|
- | - | $ 1.08 M | USA |
 |
Ra Medical Systems
RMED
|
- | 10.0 % | $ 610 K | USA |
 |
ReWalk Robotics Ltd.
RWLK
|
- | 7.07 % | $ 66.1 M | Israel |
 |
STRATA Skin Sciences
SSKN
|
- | - | $ 6.6 M | USA |
 |
Abbott Laboratories
ABT
|
$ 113.4 | -1.85 % | $ 197 B | USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 159.59 | -3.22 % | $ 11.6 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 100.8 | 1.39 % | $ 58.9 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
CONMED Corporation
CNMD
|
$ 52.72 | -1.77 % | $ 1.64 B | USA |
 |
Sintx Technologies
SINT
|
$ 1.62 | -2.41 % | $ 4.49 M | USA |
 |
MiMedx Group
MDXG
|
$ 3.27 | 2.03 % | $ 483 M | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 17.91 | -5.98 % | $ 1.22 B | USA |
 |
Myomo
MYO
|
$ 1.19 | -8.85 % | $ 49.8 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.25 | -11.7 % | $ 16.2 M | Israel |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Orthofix Medical
OFIX
|
$ 8.65 | -11.01 % | $ 343 M |  Curacao |
 |
Insulet Corporation
PODD
|
$ 154.6 | -6.31 % | $ 10.9 B | USA |